ClinicalTrials.gg
CompletedNCT01192152Updated May 12, 2015Results posted

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

A Phase 1 interventional study of saxagliptin and Glucophage XR in Diabetes Mellitus, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-12.

Sponsored by AstraZeneca · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies testing saxagliptin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. saxagliptin · Diabetes Mellitus.

Enrollment
8th of 10
30 · median 66
Started
2009
with 1 other
Phase 1
3 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
7 of 10
AstraZeneca

Among the 10 studies testing saxagliptin in Diabetes Mellitus, this one is the 8th largest by enrollment, is one of 2 that started in 2009, is one of 3 in phase 1, and was the 4th registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 10 studies testing saxagliptin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →

About saxagliptin

saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing saxagliptin in Diabetes Mellitus as a file.
02

Study summary

The purpose of this study is to demonstrate bioequivalence (BE) of a 5 mg saxagliptin/1000 mg metformin extended release (XR) fixed-dose combination (FDC) tablet (manufactured in Mt Vernon, Indiana) relative to a coadministered 5 mg Onglyza tablet (saxagliptin, manufactured in Mt Vernon, Indiana) and two 500 mg Glucophage XR tablets (metformin XR, manufactured in Evansville, Indiana) in the fed state in healthy subjects.

Read the detailed description

This study is designed to evaluate if the FDC tablet of 5 mg saxagliptin/1000 mg metformin extended release (manufactured in Mt Vernon, Indiana) is bioequivalent to the coadministered 5 mg saxagliptin tablet plus 2 x 500 mg Glucophage XR tablets (manufactured in Evansville, Indiana)

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects as determined by no deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
  • (BMI) of 18 to 32 kg/m², inclusive
  • Ages 18 to 55, inclusive

Exclusion criteria

Exclusion Criteria:

  • Evidence of organ dysfunction or any deviation from normal in physical examination, vital signs, or clinical laboratory determinations beyond what is consistent with the target population
  • Major surgical procedure within 4 weeks prior to randomization
  • Positive serology test for , or
  • Clinically significant history or presence of any of the following conditions: heart, liver, or kidney disease, neurologic or psychiatric disease
  • History of gastrointestinal disease within the past 3 months
  • Any clinically significant medical condition that could potentially affect your participation in the study and/or personal well-being, as judged by the investigator
  • Donated blood or blood products to a blood bank, blood transfusion or participated in a clinical study (except a screening visit) requiring withdrawal of blood within 4 weeks prior to randomization
  • Unable to tolerate oral and/or intravenous (IV) medications
  • Unable to tolerate the puncturing of veins for drawing of blood
  • Known allergy or to any component of the study medication
  • History of any significant drug allergies (such as anaphylaxis or hepatotoxicity)
  • Used any prescription drugs or over the counter products to control acid (for example, Prevacid, Mylanta or Rolaids) within 4 weeks prior to randomization
  • Used any other drugs including over the counter medications and herbal preparations within 1 week prior to randomization
  • Taken any drug or placebo (inactive drug) within 4 weeks prior to randomization
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    5 mg saxagliptin + 2 Glucophage XR 500 mg tablet

    Drug: saxagliptin · Drug: Glucophage XR

  • Experimental
    FDC tablet (5 mg saxa + 1000 mg metformin XR) (single dose)

    under fed state, single dose

    Drug: saxagliptin + metformin XR (FDC tablet)

  • Experimental
    FDC tablet (5 mg saxa + 1000 mg metformin XR) (4 days)

    under fed state, 4 days

    Drug: saxagliptin + metformin XR (FDC tablet)

Interventions

  • Tablets, Oral, 5 mg, once daily, Single dose

    Also known as: Onglyza

  • Tablets, Oral, 500 mg, once daily, Single dose

  • Drugsaxagliptin + metformin XR (FDC tablet)

    Drug pages: Saxagliptin · Metformin

    Tablet, Oral, (saxagliptin 5 mg)(metformin XR 1000 mg), once daily, 4 days

    Also known as: Onglyza

06

What researchers measure

Primary outcomes

  1. Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])

    Time frame: Periods 1 and 2: pre-dosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours post-dosing.

  2. Saxagliptin Observed Maximum Plasma Concentration (Cmax)

    Time frame: Periods 1 & 2: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 & 48 hrs post-dosing. Period 3: predosing on Days 2 & 3; predosing, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hrs postdosing on Day 4

  3. Metformin AUC(0-inf)

    Time frame: Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.

  4. Metformin Cmax

    Time frame: Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4.

Secondary outcomes

  1. Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])

    Time frame: Periods 1 and 2: pre-dosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours post-dosing.

  2. Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the End of the Dosing Interval (AUC[0-tau])

    Dosing interval = 24 hours.

    Time frame: Period 3: pre-dosing on Days 2 and 3; pre-dosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours post-dosing on Day 4.

  3. Saxagliptin Trough (Predose) Plasma Concentration (Cmin)

    Time frame: Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.

  4. Saxagliptin Average Plasma Concentration Over the Dosing Period (Cavg)

    Time frame: Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.

  5. Saxagliptin Degree of Fluctuation Over the Dosing Interval (Fluctuation %)

    Time frame: Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.

  6. Saxagliptin Terminal Half-life (T1/2)

    Time frame: Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.

  7. Saxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf])

    Time frame: Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.

  8. Saxagliptin Time to Achieve the Observed Maximum Plasma Concentration (Tmax)

    Time frame: Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4.

  9. 5-hydroxy Saxagliptin AUC(0-inf)

    Time frame: Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.

  10. 5-hydroxy Saxagliptin AUC(0-t)

    Time frame: Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.

  11. 5-hydroxy Saxagliptin AUC(0-tau)

    Time frame: Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.

  12. 5-hydroxy Saxagliptin Cmax

    Time frame: Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4.

  13. 5-hydroxy Saxagliptin Cmin

    Time frame: Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.

  14. 5-hydroxy Saxagliptin Cavg

    Time frame: Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.

  15. 5-hydroxy Saxagliptin Fluctuation %

    Time frame: Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.

  16. 5-hydroxy Saxagliptin T1/2

    Time frame: Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours post-dosing.

  17. 5-hydroxy Saxagliptin AUC(0-t)/AUC(0-inf)

    Time frame: Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.

  18. 5-hydroxy Saxagliptin Tmax

    Time frame: Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4.

  19. Metformin AUC(0-t)

    Time frame: Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.

  20. Metformin AUC(0-tau)

    Time frame: Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.

  21. Metformin Cmin

    Time frame: Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.

  22. Metformin Cavg

    Time frame: Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.

  23. Metformin Fluctuation %

    Time frame: Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.

  24. Metformin T1/2

    Time frame: Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.

  25. Metformin AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf])

    Time frame: Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.

  26. Metformin Tmax

    Time frame: Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4.

  27. Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

    Time frame: AEs: from initiation of study drug administration on morning of Day 1/Period 1 through study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or participation in study if last scheduled visit occurred later.

  28. Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities

    Abnormalities considered clinically significant and/or reported as an AE by the investigator.

    Time frame: From Day 1 of Period 1 to Day 3 of Period 2 for participants in Treatment Sequence BA and Day 5 of Period 3 for participants in Treatment Sequence ABC

07

Results

Posted May 17, 2011

Participant flow

Period 1
Participant flow — Period 1
MilestoneTreatment Sequence ABCTreatment Sequence BA
Started1515
Completed1514
Not completed01
Withdrew: Left prematurely (while on treatment b)01
Period 2
Participant flow — Period 2
MilestoneTreatment Sequence ABCTreatment Sequence BA
Started1514
Completed1514
Not completed00
Period 3
Participant flow — Period 3
MilestoneTreatment Sequence ABCTreatment Sequence BA
Started150
Completed140
Not completed10
Withdrew: Family emergency10

Outcome measures

PrimarySaxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])
Time frame:
Periods 1 and 2: pre-dosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours post-dosing.
Reported as:
Mean · ng*hr/mL
Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])
ng*hr/mLTreatment ATreatment BTreatment C
Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])99.45 ± 18.34105.28 ± 23.14—
Statistical analysis
  • Treatment A vs Treatment B · Ratio of geometric least squares means: 1.045 · 90% CI 1.025 to 1.065Ratio = Treatment B/Treatment A. Geometric least squares means values presented in other statistical analysis entries.
  • Treatment B · Geometric least squares mean (ng*hr/ml): 103.05
  • Treatment A · Geometric least squares mean (ng*hr/ml): 98.61
SecondarySaxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])
Time frame:
Periods 1 and 2: pre-dosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours post-dosing.
Reported as:
Mean · ng*hr/mL
Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])
ng*hr/mLTreatment ATreatment BTreatment C
Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])97.76 ± 17.96103.34 ± 22.73—
Statistical analysis
  • Treatment A vs Treatment B · Ratio of geometric least squares means: 1.035 · 90% CI 1.009 to 1.062Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment B · Geometric least squares mean (ng*hr/ml): 101.16
  • Treatment A · Geometric least squares mean (ng*hr/ml): 97.72
SecondarySaxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the End of the Dosing Interval (AUC[0-tau])

Dosing interval = 24 hours.

Time frame:
Period 3: pre-dosing on Days 2 and 3; pre-dosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours post-dosing on Day 4.
Reported as:
Mean · ng*hr/mL
Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the End of the Dosing Interval (AUC[0-tau])
ng*hr/mLTreatment ATreatment BTreatment C
Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the End of the Dosing Interval (AUC[0-tau])——19.20 ± 20.68
PrimarySaxagliptin Observed Maximum Plasma Concentration (Cmax)
Time frame:
Periods 1 & 2: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 & 48 hrs post-dosing. Period 3: predosing on Days 2 & 3; predosing, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hrs postdosing on Day 4
Reported as:
Mean · ng/mL
Saxagliptin Observed Maximum Plasma Concentration (Cmax)
ng/mLTreatment ATreatment BTreatment C
Saxagliptin Observed Maximum Plasma Concentration (Cmax)25.28 ± 6.4025.75 ± 6.9225.75 ± 7.13
Statistical analysis
  • Treatment A vs Treatment B · Ratio of geometric least squares mean: 0.999 · 90% CI 0.948 to 1.053Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment B · Geometric least squares mean (ng*hr/ml): 24.85
  • Treatment A · Geometric least squares mean (ng*hr/ml): 24.88
SecondarySaxagliptin Trough (Predose) Plasma Concentration (Cmin)
Time frame:
Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.
Reported as:
Mean · ng/mL
Saxagliptin Trough (Predose) Plasma Concentration (Cmin)
ng/mLTreatment ATreatment BTreatment C
Saxagliptin Trough (Predose) Plasma Concentration (Cmin)——0.28 ± 0.10
SecondarySaxagliptin Average Plasma Concentration Over the Dosing Period (Cavg)
Time frame:
Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.
Reported as:
Mean · ng/mL
Saxagliptin Average Plasma Concentration Over the Dosing Period (Cavg)
ng/mLTreatment ATreatment BTreatment C
Saxagliptin Average Plasma Concentration Over the Dosing Period (Cavg)——4.13 ± 0.86
SecondarySaxagliptin Degree of Fluctuation Over the Dosing Interval (Fluctuation %)
Time frame:
Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.
Reported as:
Mean · percentage of fluctuation
Saxagliptin Degree of Fluctuation Over the Dosing Interval (Fluctuation %)
percentage of fluctuationTreatment ATreatment BTreatment C
Saxagliptin Degree of Fluctuation Over the Dosing Interval (Fluctuation %)——611.85 ± 107.36
SecondarySaxagliptin Terminal Half-life (T1/2)
Time frame:
Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.
Reported as:
Mean · ng*hr/mL
Saxagliptin Terminal Half-life (T1/2)
ng*hr/mLTreatment ATreatment BTreatment C
Saxagliptin Terminal Half-life (T1/2)8.69 ± 3.718.85 ± 4.47—
SecondarySaxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf])
Time frame:
Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.
Reported as:
Mean · ratio
Saxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf])
ratioTreatment ATreatment BTreatment C
Saxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf])0.981 ± 0.0100.982 ± 0.008—
SecondarySaxagliptin Time to Achieve the Observed Maximum Plasma Concentration (Tmax)
Time frame:
Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4.
Reported as:
Mean · hour
Saxagliptin Time to Achieve the Observed Maximum Plasma Concentration (Tmax)
hourTreatment ATreatment BTreatment C
Saxagliptin Time to Achieve the Observed Maximum Plasma Concentration (Tmax)1.88 ± 0.871.51 ± 0.641.35 ± 0.51
Secondary5-hydroxy Saxagliptin AUC(0-inf)
Time frame:
Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.
Reported as:
Mean · ng*hr/mL
5-hydroxy Saxagliptin AUC(0-inf)
ng*hr/mLTreatment ATreatment BTreatment C
5-hydroxy Saxagliptin AUC(0-inf)298.80 ± 69.32296.99 ± 69.35—
Secondary5-hydroxy Saxagliptin AUC(0-t)
Time frame:
Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.
Reported as:
Mean · ng*hr/mL
5-hydroxy Saxagliptin AUC(0-t)
ng*hr/mLTreatment ATreatment BTreatment C
5-hydroxy Saxagliptin AUC(0-t)293.06 ± 68.28289.37 ± 68.72—
Secondary5-hydroxy Saxagliptin AUC(0-tau)
Time frame:
Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.
Reported as:
Mean · ng*hr/mL
5-hydroxy Saxagliptin AUC(0-tau)
ng*hr/mLTreatment ATreatment BTreatment C
5-hydroxy Saxagliptin AUC(0-tau)——318.47 ± 54.95
Secondary5-hydroxy Saxagliptin Cmax
Time frame:
Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4.
Reported as:
Mean · ng/mL
5-hydroxy Saxagliptin Cmax
ng/mLTreatment ATreatment BTreatment C
5-hydroxy Saxagliptin Cmax54.69 ± 17.0051.32 ± 16.1959.87 ± 13.83
Secondary5-hydroxy Saxagliptin Cmin
Time frame:
Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.
Reported as:
Mean · ng/mL
5-hydroxy Saxagliptin Cmin
ng/mLTreatment ATreatment BTreatment C
5-hydroxy Saxagliptin Cmin——1.51 ± 0.22
Secondary5-hydroxy Saxagliptin Cavg
Time frame:
Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.
Reported as:
Mean · ng/mL
5-hydroxy Saxagliptin Cavg
ng/mLTreatment ATreatment BTreatment C
5-hydroxy Saxagliptin Cavg——13.27 ± 2.29
Secondary5-hydroxy Saxagliptin Fluctuation %
Time frame:
Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.
Reported as:
Mean · percentage of fluctuation
5-hydroxy Saxagliptin Fluctuation %
percentage of fluctuationTreatment ATreatment BTreatment C
5-hydroxy Saxagliptin Fluctuation %——437.09 ± 43.97
Secondary5-hydroxy Saxagliptin T1/2
Time frame:
Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours post-dosing.
Reported as:
Mean · ng*hr/mL
5-hydroxy Saxagliptin T1/2
ng*hr/mLTreatment ATreatment BTreatment C
5-hydroxy Saxagliptin T1/213.48 ± 1.7813.82 ± 2.52—
Secondary5-hydroxy Saxagliptin AUC(0-t)/AUC(0-inf)
Time frame:
Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.
Reported as:
Mean · ratio
5-hydroxy Saxagliptin AUC(0-t)/AUC(0-inf)
ratioTreatment ATreatment BTreatment C
5-hydroxy Saxagliptin AUC(0-t)/AUC(0-inf)0.975 ± 0.0090.973 ± 0.010—
Secondary5-hydroxy Saxagliptin Tmax
Time frame:
Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4.
Reported as:
Mean · hour
5-hydroxy Saxagliptin Tmax
hourTreatment ATreatment BTreatment C
5-hydroxy Saxagliptin Tmax2.69 ± 0.802.27 ± 0.842.05 ± 0.57
PrimaryMetformin AUC(0-inf)
Time frame:
Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.
Reported as:
Mean · ng*hr/mL
Metformin AUC(0-inf)
ng*hr/mLTreatment ATreatment BTreatment C
Metformin AUC(0-inf)10336.18 ± 3066.139211.29 ± 3364.24—
Statistical analysis
  • Treatment A vs Treatment B · Ratio of geometric least squares means: 0.894 · 90% CI 0.833 to 0.959Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment B · Geometric least squares mean (ng*hr/ml): 8713.4
  • Treatment A · Geometric least squares mean (ng*hr/ml): 9746.3
SecondaryMetformin AUC(0-t)
Time frame:
Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.
Reported as:
Mean · ng*hr/mL
Metformin AUC(0-t)
ng*hr/mLTreatment ATreatment BTreatment C
Metformin AUC(0-t)9734.38 ± 3123.768846.36 ± 3304.75—
Statistical analysis
  • Treatment A vs Treatment B · Ratio of geometric least squares means: 0.906 · 90% CI 0.848 to 0.968Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment B · Geometric least squares mean (ng*hr/ml): 8377.8
  • Treatment A · Geometric least squares mean (ng*hr/ml): 9246.8
SecondaryMetformin AUC(0-tau)
Time frame:
Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.
Reported as:
Mean · ng*hr/mL
Metformin AUC(0-tau)
ng*hr/mLTreatment ATreatment BTreatment C
Metformin AUC(0-tau)——9501.81 ± 4001.00
PrimaryMetformin Cmax
Time frame:
Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4.
Reported as:
Mean · ng/mL
Metformin Cmax
ng/mLTreatment ATreatment BTreatment C
Metformin Cmax1184.07 ± 276.121078.67 ± 221.72979.93 ± 267.58
Statistical analysis
  • Treatment A vs Treatment B · Ratio of geometric least squares means: 0.917 · 90% CI 0.859 to 0.980Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment B · Geometric least squares mean (ng*hr/ml): 1055.9
  • Treatment A · Geometric least squares mean (ng*hr/ml): 1151.2
SecondaryMetformin Cmin
Time frame:
Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.
Reported as:
Mean · ng/mL
Metformin Cmin
ng/mLTreatment ATreatment BTreatment C
Metformin Cmin——105.04 ± 88.09
SecondaryMetformin Cavg
Time frame:
Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.
Reported as:
Mean · ng/mL
Metformin Cavg
ng/mLTreatment ATreatment BTreatment C
Metformin Cavg——395.91 ± 166.71
SecondaryMetformin Fluctuation %
Time frame:
Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.
Reported as:
Mean · percentage of fluctuation
Metformin Fluctuation %
percentage of fluctuationTreatment ATreatment BTreatment C
Metformin Fluctuation %——240.06 ± 73.54
SecondaryMetformin T1/2
Time frame:
Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.
Reported as:
Mean · ng*hr/mL
Metformin T1/2
ng*hr/mLTreatment ATreatment BTreatment C
Metformin T1/213.02 ± 6.1512.94 ± 6.74—
SecondaryMetformin AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf])
Time frame:
Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.
Reported as:
Mean · ratio
Metformin AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf])
ratioTreatment ATreatment BTreatment C
Metformin AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf])0.967 ± 0.0290.963 ± 0.034—
SecondaryMetformin Tmax
Time frame:
Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4.
Reported as:
Mean · hour
Metformin Tmax
hourTreatment ATreatment BTreatment C
Metformin Tmax4.38 ± 0.734.84 ± 0.915.00 ± 1.30
SecondarySafety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

Time frame:
AEs: from initiation of study drug administration on morning of Day 1/Period 1 through study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or participation in study if last scheduled visit occurred later.
Reported as:
Number · participants
Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)
participantsTreatment ATreatment BTreatment C
Number of Participants With At Least 1 AE334
Discontinuation Due to AE000
Deaths000
SAEs000
SecondarySafety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities

Abnormalities considered clinically significant and/or reported as an AE by the investigator.

Time frame:
From Day 1 of Period 1 to Day 3 of Period 2 for participants in Treatment Sequence BA and Day 5 of Period 3 for participants in Treatment Sequence ABC
Reported as:
Number · participants
Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities
participantsTreatment ATreatment BTreatment C
Clinical Laboratory Abnormalities000
Vital Sign Abnormalities000
Physical Examination Abnormalities001
12-Lead ECG Abnormalities000

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Saxa 5mg + 2x500mg Metformin, Fed—0/29 (0%)3/29 (10.3%)
Saxa 5mg/1000mg Metformin, Fed—0/30 (0%)3/30 (10%)
Saxa 5mg/500mg Metformin, Fed 4 Days—0/14 (0%)4/14 (28.6%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventSaxa 5mg + 2x500mg Metformin, FedSaxa 5mg/1000mg Metformin, FedSaxa 5mg/500mg Metformin, Fed 4 Days
DYSURIARenal and urinary disorders0/290/302/14
NAUSEAGastrointestinal disorders1/290/301/14
DRY MOUTHGastrointestinal disorders1/290/301/14
TOOTHACHEGastrointestinal disorders0/290/301/14
ABDOMINAL PAINGastrointestinal disorders0/290/301/14
APHTHOUS STOMATITISGastrointestinal disorders0/290/301/14
ABDOMINAL DISTENSIONGastrointestinal disorders0/290/301/14
ACNESkin and subcutaneous tissue disorders0/290/301/14
VAGINAL DISCHARGEReproductive system and breast disorders0/290/301/14
VULVOVAGINAL PRURITUSReproductive system and breast disorders0/290/301/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Enrolled and Treated Participants
Mean31.6 ± 7.76
Sex: Female, Male
Sex: Female, Male(Participants)All Enrolled and Treated Participants
Female17
Male13
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)All Enrolled and Treated Participants
White22
Black or African American8
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)All Enrolled and Treated Participants
Hispanic or Latino13
Not Hispanic or Latino17
Height
Height(cm)All Enrolled and Treated Participants
Mean166.85 ± 9.02
Weight
Weight(kg)All Enrolled and Treated Participants
Mean71.56 ± 9.39
Body Mass Index
Body Mass Index(kg/m^2)All Enrolled and Treated Participants
Mean25.69 ± 2.70
08

Study locations

1 site
  • PPD Development, LP
    Austin, Texas 78744, United States
09

References and documents

Publications

  • Boulton DW, Smith CH, Li L, Huang J, Tang A, LaCreta FP. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects. Clin Drug Investig. 2011;31(9):619-30. doi: 10.2165/11590290-000000000-00000. PubMed 21819160 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2010
First posted
Aug 31, 2010
Start
Nov 2009
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
May 17, 2011
Last update
May 12, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01192152
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 31, 2010
Start date
Nov 2009
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
May 17, 2011
Last update
May 12, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Saxagliptin · Extended Release Metformin Hydrochloride · Metformin

Start the discussion